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allowing maximum doses of ~125% (SRS) using both fixed field 
IMRT and VMAT techniques. 
 
Material and Methods: A systematic literature search was 
undertaken to assess pelvic re-irradiation outcomes and 
cumulative dose constraints for organs at risk including 
bowel, bladder and rectum were derived. Dosimetric 
assessment was undertaken for 10 patients treated for 
recurrent gynaecological cancer assuming prior pelvic 
radiotherapy of 50Gy (EQD2). Plans were produced to deliver 
30Gy in 5 fractions using ICRU-fixed, ICRU-VMAT, SRS-fixed 
and SRS-VMAT techniques. Doses to GTV, PTV and OAR were 
compared and conformity index measured for each 
technique. 
 
Results: All 50 plans met the planning objectives for PTV and 
GTV coverage. PTV volume ranged from 10 – 99 cc (mean 38 
cc). Mean GTV dose with ICRU-fixed and ICRU-VMAT was 
30.1Gy; with SRS-fixed and SRS-VMAT it was 30.4 Gy, 
increasing the EQD210 from 40 Gy to 48.4 Gy. Conformity 
index was ICRU-fixed1.19, ICRU-VMAT 1.10, SRS-fixed 1.04 
and SRS-VMAT 1.05. All bladder and rectal targets were met 
for all plans except one patient with bladder involvement. 
The dose limiting structure was bowel with mean Dmax 27 Gy 
(range 13-33 Gy), D2cc 21 Gy (13-30), D5cc 17 Gy (7-27) and 
no significant differences between techniques. Dose targets 
were exceeded for 3 patients with no correlation to PTV 
volume, only proximity of GTV to bowel.  
 
Conclusion: Re-irradiation is a valuable option for treating 
sidewall recurrence and can be delivered within acceptable 
dose constraints with both normalisation techniques. SRS 
type normalisation increases mean GTV doses by 21% (EQD2) 
compared to ICRU normalisation without increasing OAR 
doses. Using our proposed bowel tolerances of Dmax 31 Gy, 
D2cc 27.1 Gy, D5cc 18.1 Gy, there is potential for further 
dose escalation in 50-70% patients.  
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Purpose or Objective: Volumetric Modulated Arc Therapy 
(VMAT) is a novel variation of Intensity Modulation 
Radiotherapy (IMRT) which allows to deliver dose during the 
beam rotation with a variable dose rate. The main advantage 
of this technique is treatment time shortening, what may be 
crucial especially due to a risk of intrafraction motion. On 
the other hand not only the treatment time but also a plan 
quality should be taken into account. The aim of this study 
was to compare VMAT hypofractionated post-mastectomy 
chest wall RT plans with IMRT plans. 
 
Material and Methods: Plans for seventeen patients with 
post-mastectomy chest wall radiotherapy were selected for 
the study. The clinical target volume included chest wall and 
internal mammary nodes. The prescribed dose (PD) were: 
40.05 Gy delivered in 15 fractions (5 – left side; 3 – right side) 
and 40.5 Gy delivered in 15 fractions (4 – left side; 5 – right 
side). For each patient IMRT and VMAT plans were generated. 
The dose distribution was prescribed to the mean dose to the 
CTV. The comparison was made on the basis of: the volume 
of CTV and PTV which receives 90% and 95% of prescribed 
dose, the volume of the ipsilateral lung which receives 20 Gy 
or more (VL20), the mean dose to the ipsilateral lung, the 
volume of the heart which receives 20 Gy or more (VH20), 
the mean dose to the heart, the total volume of both lungs 
which received 20Gy (VLR20) and 30 Gy (VLR30) or more, the 
mean dose to the both lungs, the maximum dose to the spinal 
cord and the number of monitor units (MU) per single 
fraction. For statistical analysis, the Wilcoxon matched-pairs 
signed-ranks test was used. 
 
Results: All treatment plans fulfilled dose volume constrains 
for CTV, PTV and OAR regardless of the technique used. 
There was no statistically significant difference in dose 
distribution in CTV, PTV and OAR (p > 0.05). VMAT plans 
results in a statistically significant lower number of MU 
(p=0.041 for PD = 40.05Gy and p=0.043for PD = 40.50Gy) The 
number of MU was on average 1363.6±221.1 MU and 
764.0±132.6 MU for IMRT and VMAT plans, respectively when 
the plans with PD of 40.05Gy were analyzed. Similar results 
were obtained for plans with PD of 40.50 Gy (on average 
1010.2±57.4 MU vs 775.4±76.7 MU for IMRT and VMAR 
respectively). 
 
Conclusion: VMAT in comparison with IMRT technique 
improves efficacy of plan delivery for equivalent plan quality. 
The decreased number of monitor units allows to deliver a 
single fraction faster, so it to reduce the probability of 
intrafraction motion. 
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Purpose or Objective: Flattening filter free (FFF) beams are 
most frequently utilized for treatments where higher fraction 
doses need to be delivered, including hypofractioned 
stereotactic body radiation therapy (SBRT). There are various 
treatment modalities now available for SBRT: conventional 
static fields, dynamic conformal arc (DCA) or Volumetric 
Modulated Arc Therapy (VMAT). In the present study, we 
wanted to obtain some criteria for a conscious choice of the 
employment of FFF beams and of the DCA or RA technique 
depending the size of the PTV.  
 
Material and Methods: Treatment planning was carried out 
using version 11 of Eclipse (Varian, Palo Alto, CA, USA) with 
Analytical Anisotropic Algorithm (AAA). All plans were 
designed for a Varian TrueBeam STx linear accelerator 
(Varian Medical Systems) equipped with a high definition 
Millenium multi-leaf collimator (HDMLC). Twenty four PTVs 
from 1.52 cm3 to 445.24 cm3 were studied. For each PTV, 
DCA and VMAT plans were prepared utilizing two flattened 
photon beam of 6 MV (6FF) and 10 MV (10FF) and two 
nonflattened beams of nominal energy 6 and 10 MV (6FFF, 
10FFF). For a meaningful comparison, all DCA and RA plans 
satisfied 100% of the prescription dose to at least 98% of the 
PTV. Parameters such as conformity index, gradient index, 
healthy tissue mean dose, organs at risk mean dose, number 
of monitor units, beam on time (BOT) were used to quantify 
obtained dose distributions. A friedman and spearman’s rho 
test were performed in order to establish statistical 
significance. 
 
Results: The data indicate no significant differences between 
conformity with flattened beams and those using unflattened 
beams for VMAT technique. For DCA technique, it is notable 
that 6FFF tends to be slightly better than 6FF beams and 
even for large volumes. As PTV volume increases, 10FFF is 
less suitable for DCA technique and forward planning 
becomes more challenging and inappropriate. The MUs in the 
FFF plans were always greater than in FF plans. Dose to 
healthy tissues were reduced for all PTV sizes for FFF beams, 
except for the DCA 10FFF for large PTV volume. The BOT for 
FFF beams is much lower. DCA was found to be more 
appropriate for small PTV and VMAT for median and large 
PTV. The MUs were significantly different between 
techniques. VMAT plans generated larger number of MU 
compared to DCA. 
 
Conclusion: The plans developed with flattened and 
unflattened beams look very similar in terms of conformity 
index. FFF beams provide a better sparing of OAR except for 
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DCA 10FFF and reduced treatment times when compared to 
FF. Further study on the role of tumor location is 
recommended to establish more conclusive results. A concern 
with the use of VMAT with SBRT is whether the motion of the 
tumor leads to significant dosing discrepancies. DCA remains 
immune to the MLC interplay effect. 
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Purpose or Objective: To modify helical irradiation of the 
total skin (HITS) technique as the completed-HITS (CHITS) 
with face covering and the bone marrow dose declined 
according to the relapse pattern and hematologic toxicities 
of cutaneous lymphoma patient. 
 
Material and Methods: A 36-year-old woman was diagnosed 
as therapy-refractory cutaneous CD4+ T-cell lymphoma, 
T3N0M0B0, stage IIB. HITS with face sparing using 30 Gy in 40 
fractions, 4 times per week was prescribed in March, 2012. 
The adverse effects included leukopenia. One year later, the 
new patches were noted in right eyebrow and lower eyelid 
which was spared. According to the relapse pattern and 
hematologic toxicities, HITS was revised to improve the plan 
results as CHITS. First, the clinical target volume (CTV) was 
increasing the face targeting to be really whole skin 
irradiated. Second, the planning target volume (PTV) were 
separated into head, chest, abdomen and pelvis with upper 
thigh to maintaining the appropriate PTV coverage and the 
margin for PTV was reduced from 5.0 mm to 3.0 mm 
according to the previous daily image-guided data. Third, the 
central cord complete block (CCCB) was designed from head 
to thigh but not from head to abdomen only. The CCCB 
distance away from PTV was changed from 2.5 cm to 2.2 cm 
to reduce the internal organs and bone marrow dose. 
Additionally, the iliac bone, cervical, thoracic, lumbar spine, 
femoral head and pelvic bone were contoured to be 
references to limit the marrow dose. The uniformity index 
(UI), conformity index (CI), dose of organs at risk were used 
to evaluate the plans. For reducing the toxicity of normal 
organs, we also performed low-dose CHITS of 12 Gy in 12 
fractions. 
 
Results: The UI for head, chest, abdomen and pelvis of CHITS 
were 1.16, 1.12, 1.08 and 1.15 that were similar to HITS of 
1.12, 1.12, 1.08 and 1.12, respectively. For the low-dose 
CHITS, the UI is also similar to CHITS. The conformity of 
CHITS was similar to HITS (1.40 versus 1.37). The mean dose 
of heart, whole lung, right parotid gland, left parotid gland, 
liver, right kidney, left kidney, intestine, bladder, rectum, 
uterus with ovary, and cervix with vagina were reduced in 
15.1% to 45.0%. The mean dose of cervical spine, thoracic 
spine, lumbar spine, right iliac bone, left iliac bone, sacrum, 
right lower pelvic bone, left lower pelvic bone, right femur, 
left femur were reduced in 21.6% to 63.8%. For the low-dose 
CHITS, the normal organ dose were reduced in 47% to 88% 
due to low dose treatment. 
 
Conclusion: The modifications of adding face skin irradiation, 
reduced PTV margin, the distance away from PTV from CCCB 
and virtual structure constraints enabled the CHITS technique 
reduced doses of normal organs and bone marrow 
successfully with keep of uniformity and conformity as HITS 
technique. The low-dose CHITS had the similar results in 
target uniformity and conformity and much lower normal 
organ dose compared to HITS technique. 
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Purpose or Objective: The theoretical benefit of dose 
escalation in NSCLC has been shown by Fenwick whilst others 
have demonstrated a clinical dose response relationship 
(Partridge, Rengan). Additionally, inhomogeneous dose 
distributions have been suggested as a method for increasing 
the absolute dose to the target within normal tissue 
constraints (Warren). The aim of this planning study was to 
combine these concepts and explore the potential tumour 
control probability (TCP) benefit that an inhomogeneous plan 
targeting dose escalation to the iGTV could deliver whilst 
respecting normal tissue tolerances. 
 
Material and Methods: Between January 2014 and April 2015 
20 patients with non-small cell lung cancer (NSCLC) 
underwent 4D-planning CT with motion tracking via the RPM 
system (Varian Medical Systems, Palo Alto, California) for 
definitive (chemo)radiation therapy at our institution. The 
4DCT scan was binned into 10 phases and the MIP and AVIP 
datasets were generated. The iGTVsum was the sum of three 
datasets (0%, 50% and MIP). An iGTV to iCTV margin of 6mm 
(scc) or 8mm (adenocarcinoma) was used with a further 5mm 
to the PTV. OARS were contoured on the AVIP CT set, 
including: combined lung; spinal cord; oesophagus and heart. 
Mean iGTVsum volume of 94.51cm3 (range: 12.44 – 
608.69cm3) and mean PTV volume of 315.51cm3 (range: 
97.02 – 1279.64cm3). Six plans were created: homogeneous 
plans treating the entire PTV to 60Gy in 20 fractions using 
both 3DCRT and RapidArc; and four inhomogeneous RapidArc 
plans developed to deliver 65-80Gy in 5Gy escalated 
increments to iGTVsum (median) and 60Gy to PTV, all in 20 
fractions. 
 
Results: There is a significant (p < 0.05) difference in TCP for 
all escalated plans, ranging from 79.8% for the 65Gy boost to 
94.9% for the 80Gy boost, in comparison to 63.1% for the 
homogeneous RapidArc plan. There is a significant difference 
between the MLD for the various escalated plans (Table 1); 
however, this difference is not clinically significant given 
that tolerance for MLD is in the 17-20Gy region. Similarly, the 
predicted NTCP for the lung for the dose escalated plans 
ranged from 6.2-7.1%. In terms of the V20Gy the only 
significant difference was between the 3D plan and all the 
RapidArc plans (Table 1).  
 
 
The only significant mean oesophageal difference was 
between the 3D plan (20.6Gy) and all the escalated plans 
(17.7-18Gy); however, dose to 1cc of the oesophagus was 
significantly higher for the 80Gy and 3D plans. All spinal cord 
and heart doses were below tolerance for the escalated 
plans. 
